Loading...
  • Ovarian Cancer
  • Identification and development of highly sensitive and specific tumor markers for the detection and management of ovarian cancer and other gynecological malignancies [ Time Frame: Outcomes will be assessed at the completion of the study. (clinicaltrials.gov)
  • Identification of measures to improve the quality of life for women at increased risk for developing the disease and for women diagnosed with ovarian cancer [ Time Frame: Outcomes will be assessed at the completion of the study. (clinicaltrials.gov)
  • Women who are at increased risk of ovarian cancer based on family or personal medical history who are participating in the Northwestern Ovarian Cancer Early Detection and Prevention Program clinic. (clinicaltrials.gov)
  • Subject's blood collected at their follow-up blood draw will be assessed for biomarkers that could lead to a panel for detecting early stage ovarian cancer. (clinicaltrials.gov)
  • Questionnaires designed to assess quality of life for women at increased risk of ovarian cancer will be administered to the subjects. (clinicaltrials.gov)
  • To identify and develop highly sensitive and specific tumor markers for the detection and management of ovarian cancer and other gynecological malignancies. (clinicaltrials.gov)
  • Participants may have samples of blood, tissue, or body fluids (such as ascites, pleural fluid or urine), or any combination of the aforementioned samples obtained to develop tumor markers to detect early stage or recurrent ovarian cancer. (clinicaltrials.gov)
  • In the future, if any of the experimental tumor markers are found to be effective in detecting early stage ovarian cancer, and the patient's result is abnormal, the patient and physician will be notified. (clinicaltrials.gov)
  • The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction. (medworm.com)
  • Cancers that are known to have a hereditary link are breast cancer, colon cancer, ovarian cancer , and uterine cancer. (thefreedictionary.com)
  • Rare Cancers
  • I. To evaluate the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy. (clinicaltrials.gov)
  • Recurrence
  • Good routine care and patient education provide the most useful information for detecting recurrence of gynecologic cancers, according to new recommendations for post-treatment surveillance. (cancer.org)
  • Point out that this report indicates that there is very little evidence that either routine cytologic procedures or imaging are sufficiently useful to detect ovarian and endometrial cancer recurrence and alter response rates to salvage therapy. (cancer.org)
  • patients
  • In vulvar cancer, the GROINS-V-II study protocol was amended to mandate inguinofemoral lymphadenectomy in all patients with SLN macrometastasis greater than 2 mm after unacceptably high rates of groin recurrences were observed on interim analysis. (springer.com)
  • SLN mapping is now included in the treatment guidelines of the National Comprehensive Cancer Network guidelines for endometrial, cervical, and vulvar cancer as an acceptable lymphatic assessment technique in select patients. (springer.com)
  • In patients with vulvar cancer, SLN biopsy is an acceptable standard of care for patients with unifocal tumors, less than 4 cm in largest diameter, and clinically and radiographically negative groin nodes. (springer.com)
  • Participating in a stress reduction program may help improve quality of life in patients with gynecologic or breast cancer. (clinicaltrials.gov)
  • At least 20% of patients will develop lower-limb lymphoedema following gynaecological cancer treatment. (clinicaltrials.gov)
  • Patients who develop lymphoedema after gynaecological cancer treatment, will experience increased pain, lower quality of life (including worse body-image), and decreased sexual & financial well-being, compared to those who do not develop lymphoedema. (clinicaltrials.gov)
  • There will be at least 10% difference in the incidence of lower-limb lymphoedema between patients treated for gynaecological cancer compared to benign diseases. (clinicaltrials.gov)
  • Prevalence of key risk factors of post-treatment lymphoedema among patients with gynaecological cancer. (clinicaltrials.gov)
  • Lymphoedema development in patients treated for gynaecological cancer compared to patients with benign disease. (clinicaltrials.gov)
  • RATIONALE: Gathering information from patients who have undergone treatment for upper gastrointestinal cancer or gynecological cancer may help doctors learn more about patients' physical and psychosocial rehabilitation needs and plan the best treatment. (clinicaltrials.gov)
  • PURPOSE: This clinical trial is studying the physical and psychosocial rehabilitation needs of patients after diagnosis and treatment of upper gastrointestinal cancer or gynecological cancer. (clinicaltrials.gov)
  • To explore the patients' perspective of their physical and psychosocial rehabilitation needs following the diagnosis and treatment for an upper gastrointestinal or a gynecological cancer. (clinicaltrials.gov)
  • To assess patients' experiences of the physical and social impact of cancer in the treatment and post-treatment phase. (clinicaltrials.gov)
  • This randomized phase II trial studies how well psychosexual intervention works in patients with stage I-III gynecologic or breast cancer. (clinicaltrials.gov)
  • Patients participate in enhanced standard care intervention comprising stress reduction, information delivery regarding cancer treatments and sexuality delivered over two sessions. (clinicaltrials.gov)
  • ARM I (Enhanced standard care): Patients participate in enhanced standard care intervention comprising stress reduction, information delivery regarding gynecologic or breast cancer treatments and sexuality, and provision of a survivorship care plan (SCP) created using OncoLink over 1 hour following baseline assessment and before 6 months. (clinicaltrials.gov)
  • To assess the preferences of cancer patients scheduled to receive chemoradiation and caregiver controls for side-effects of chemoradiation. (clinicaltrials.gov)
  • To compare preferences of cancer patients to those of healthy individuals. (clinicaltrials.gov)
  • To longitudinally assess the quality of life of cancer patients scheduled to receive chemoradiation. (clinicaltrials.gov)
  • Determine the maximum tolerated dose of metronomic docetaxel in patients with progressive or recurrent gynecologic cancer. (clinicaltrials.gov)
  • Patients must have histologically confirmed advanced, refractory gynecologic cancer. (clinicaltrials.gov)
  • To describe the mutational load and targeted sequencing of well-known oncogenes and changes in these markers of patients at up to three time points (baseline, cycle 2, and progression), and across strata to describe associations with survival outcomes. (clinicaltrials.gov)
  • Prospective
  • A lack of data from prospective studies to support current surveillance strategies provided the impetus for the SGO Clinical Practice Committee to review the available evidence and formulate recommendations that offer gynecologic cancer survivors the best chance for long-term survival with minimal risk and acceptable cost. (cancer.org)
  • Description
  • trials) this searches for the phrase 'kidney cancer' in the title as well as either the word 'trial' or 'trials' in description. (medworm.com)
  • Type
  • Furthermore, multi-institutional retrospective studies comparing SLN mapping to traditional lymphadenectomy have found comparable survival between the two techniques, in both type 1 and type 2 endometrial cancer. (springer.com)
  • Look at uterine neoplasms and find your type and stage and see what is recommended for treatment and surveillence. (cancer.org)
  • study
  • The Head of Therapies, a representative from the Psychological Care/ Psychological Support Service and a Nurse Consultant in Living with and Beyond Cancer have been involved in the development of the protocol from the preliminary study in order to ensure its' conduct will be feasible within The Royal Marsden NHS Foundation Trust (RM). (knowcancer.com)